Director Share Transfer

RNS Number : 4548T

Futura Medical PLC

28 September 2010

 



For immediate release

28 September 2010

Futura Medical plc

("Futura" or "the Company")

Director's Share Transfer

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that David Davies, Director of Product Development, has today transferred 160,239 ordinary shares in the Company into his Hargreaves Lansdown Vantage SIPP account for no consideration.

There is no change in the beneficial ownership of these ordinary shares, and Mr Davies's holding in ordinary shares in the Company, as defined by the AIM Rules, remains unchanged as a result of the transfer at 532,572 ordinary shares, representing 0.79% of the Company's share capital.

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
Nomura Code Securities Limited
Phil Walker / Giles Balleny	Tel:[phone]
For media enquiries please contact:
Buchanan Communications
Mark Court / George Prassas	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

RDSUWVSRRKAKUAR